In NSCLC patients, the most important factors in the choice of therapy are splicing mutations (deletions, insertions, and substitutions) in introns 13 (splice donor) and 14 (splice acceptor) and in exon 14 of the MET gene (“skipping mutations”, METex14). Here, MET is linked to non-small cell lung carcinoma.